Podcasts about Amyotrophic lateral sclerosis

This Saturday, to celebrate our 200th unique program, The Word on Medicine examines Amyotrophic Lateral Sclerosis or ALS – also known as Lou Gehrig's Disease – after the New York Yankees first baseman who played 17 seasons in the big leagues and was inducted into the Baseball Hall of Fame in 1939. His baseball career came to an abrupt end when he lost his strength, power, and then the ability to make even routine plays in the field. We cover ALS in great detail with our panel of experts to include Dr. David Shirilla, who will be joined by Stacey Martinetti (RN) and Christina Wipperman (PT) from the Neuromuscular and Autonomic programs at MCW. Most importantly, we hear from a courageous patient who is dealing with ALS right now. Please listen in!

Peter Ubel is a professor of business, public policy, and medicine at Duke University. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. P.A. Ubel, A. Grouls, and A.S. Kesselheim. Out of Pocket Getting Out of Hand — Reducing the Financial Toxicity of Rapidly Approved Drugs. N Engl J Med 2025;392:729-731.

The HEALEY ALS platform is an innovative first attempt at platform trials in ALS, looking to slow ALS disease progression. Author Sabrina Paganoni, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses results of the first 4 drug regimens from this platform trial and how this study design makes efficient use of resources, with JAMA Deputy Editor Christopher Muth, MD. Related Content: Platform Clinical Trials for the Efficient Evaluation of Multiple Treatments Pridopidine in Amyotrophic Lateral Sclerosis Platform Trials in ALS Verdiperstat in Amyotrophic Lateral Sclerosis Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis CNM-Au8 in Amyotrophic Lateral Sclerosis

ALS, a nervous system disease, ruled the headlines in the summer of 2014 thanks to the viral Ice Bucket Challenge. How has our knowledge of the disorder evolved a decade later? Amyotrophic lateral sclerosis, also known as ‘Lou Gehrig's disease' (named after the iconic baseball player), is a progressive neurological disorder which breaks down a person's motor neurons. The main symptoms are muscle weakness and impaired physical function — mild, at first, but in the latter stages of the disease's progression, essential processes like breathing begin to fail. Most individuals face a life expectancy of two to five years. A small percentage live five to ten years. And an even tinier group survive beyond a decade. Most famously, renowned physicist Stephen Hawking survived more than 50 years past his diagnosis, in part due to the intensive care he was able to afford. In this episode of the ‘Your Brain On...' podcast, we discuss: • What ALS is, and how it affects the brain and the body • The onset and progression of ALS, from the earliest symptoms to the end-stage impacts • How ALS patients are diagnosed, treated, and cared for • Likely causes of ALS, including genetic predispositions and potential environmental risk factors • How new technologies are rapidly accelerating our understanding of ALS, especially in genetics Joining us for this installment of the show are two world-class experts on the disease: • Professor Ammar Al-Chalabi PhD, Professor of Neurology and Complex Disease Genetics at the Maurice Wohl Clinical Neuroscience Institute at King's College. • Merit Cudkowicz, Director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital. ‘Your Brain On' is hosted by neurologists, scientists and public health advocates Ayesha and Dean Sherzai. ‘Your Brain On... ALS' • SEASON 4 • EPISODE 3 ——— LINKS PROFESSOR AMMAR AL-CHALABI at King's College: https://www.kcl.ac.uk/people/ammar-al-chalabi at Motor Neurone Disease Disease Association: https://www.mndassociation.org/get-involved/cure-finders/professor-ammar-al-chalabi Project MinE: https://projectmine.com/ MERIT CUDKOWICZ at Massachusetts General Hospital: https://www.massgeneral.org/doctors/16904/merit-cudkowicz  at Harvard University: https://researchers.mgh.harvard.edu/profile/1520993/Merit-Cudkowicz ——— ANNOUNCING: NEURO WORLD RETREAT 2025 We're so excited to share something very close to our hearts, which we've been working on over the past few months: our first ever brain health retreat! You're warmly invited to join us in San Diego, California for the inaugural NEURO World Retreat 2025, taking place September 2–5, 2025 at the breathtaking Paradise Point Resort. For more information, and to book, visit: https://neuroworldretreat.com/ ——— FOLLOW US Join the NEURO Academy: NEUROacademy.com Instagram: @thebraindocs Website: TheBrainDocs.com More info and episodes: TheBrainDocs.com/Podcast ——— References: Brown, Robert H., and Ammar Al-Chalabi. "Amyotrophic lateral sclerosis." New England Journal of Medicine 377.2 (2017): 162-172. Benatar, Michael, et al. "A roadmap to ALS prevention: strategies and priorities." Journal of Neurology, Neurosurgery & Psychiatry 94.5 (2023): 399-402. Voigtlaender, Sebastian, et al. "Artificial intelligence in neurology: opportunities, challenges, and policy implications." Journal of Neurology 271.5 (2024): 2258-2273. Zinman, Lorne, and Merit Cudkowicz. "Emerging targets and treatments in amyotrophic lateral sclerosis." The Lancet Neurology 10.5 (2011): 481-490. Raghav, Yogindra, et al. "Identification of gene fusions associated with amyotrophic lateral sclerosis." Muscle & Nerve 69.4 (2024): 477-489. Su, Feng-Chiao, et al. "Association of environmental toxins with amyotrophic lateral sclerosis." JAMA neurology 73.7 (2016): 803-811. Talbott, Evelyn O., et al. "Case-control study of environmental toxins and risk of amyotrophic lateral sclerosis involving the national ALS registry." Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2024): 1-10.

Moderator: Federica Agosta (Milan, Italy)Guest: Philip van Damme (Leuven, Belgium) In this week's episodes Federica Agosta hosts Philip van Damme as they discuss the new EAN Guideline on the Management of Amyotrophic Lateral Sclerosis. Find more information here.

Can artificial intelligence restore speech in patients with ALS? Find out about this and more in today's PeerDirect Medical News Podcast.

originally released: July 22, 2020 • updated intro: December 23, 2020 Three-time Tony-nominee Rebecca Luker is here for a walk through her career and the show Sheldon Harnick calls our “greatest American opera.” Topics Include: getting an agent out of town, auditioning for Hal Prince, balancing your work and your life, and of course we talk about The Secret Garden and I play “How Could I Ever Know” are you kidding? Watch At Home with Rebecca Luker: An Evening of Song! All of the proceeds from the virtual benefit performance will go to supporting Prosetin, a promising new drug candidate for Amyotrophic Lateral Sclerosis. It was in February when Broadway favorite Luker revealed that she had been diagnosed with ALS (also known as Lou Gehrig's Disease). For more information about this treatment, visit Prosetin2020.org. If you would like to place a donation, click here: https://fundraise.projectals.org/give/270277/#!/donation/checkout. Featured Recordings: Sweeney Todd: the Demon Barber of Fleet Street - Original Cast (1979) • The Secret Garden - The Original Broadway Cast Album (1991) MERCH! T-shirts! Totes bags! BASEBALL SHIRTS! ETCETERA! DO YOU LIKE MOVIE MUSICALS? Join us on PATREON to get our patrons-only podcast The Original Cast at the Movies! This month is the Judy Garland installment in our A Star is Born series with Roddy Flynn and Kari Ginsburg as we tackle all 4 Stars is Born films this year! Patreon • Twitter • Facebook • Email

Tuesday marked a decade since the ALS Ice Bucket Challenge went viral online. It saw people around the world dumping ice-cold water over their heads and posting it online to nominate others, raising awareness and money for Amyotrophic Lateral Sclerosis. Host Jeff Douglas is joined by David Taylor, the vice-president of Research and Strategic Partnerships with ALS Canada, to talk about how the challenge has made a difference.

The month of May is ALS Awareness Month, and Aging Today is celebrating all the volunteers who make a difference in the lives of people living with Amyotrophic Lateral Sclerosis. Annie Teer, Volunteer Coordinator from ALS Northwest leads the volunteer program. Along with all the many people who provide personal assistance, many types of assistive technologies help people live their best lives. Ashley Loyning, Assistive Technology Coordinator makes it happen.

Guest: Emily Kornman, MCD, CCC-SLP - Emily brings Team Gleason to you in this one-hour conversational audio course podcast. Team Gleason is a 5013(c)(3) organization founded in 2011 by Steve and Michel Gleason - Team Gleason has provided over $40 million in adventure, technology, equipment, and care services to people living with Amyotrophic Lateral Sclerosis (ALS) and countless others through advocacy and support. Emily highlights how Team Gleason supports people with ALS and their families with an interdisciplinary approach. She describes how SLPs can support speech, swallowing, voice preservation, and AAC options to empower people with ALS to live purposeful lives.

May is ALS Awareness Month, and joining us on the Aging Today Podcast are three incredible people who coordinate the care for anyone diagnosed with Amyotrophic Lateral Sclerosis here in Oregon. Mary Rebar, Christina Riddock, and Laura Geilenfeldt are all Care Services Coordinators who provide expert advice and assistance for anyone diagnosed and living with ALS. Tune in to hear their stories about how they are making a difference.

Lindsey Vonn, an American sporting icon, needs no introduction. She's not just a skier; she's a force of nature. In this episode, Lindsey sits down with Ryan Manion of Travis Manion Foundation and explores the mindset, resilience, and relentless pursuit of excellence that propelled her to become one of the most decorated female skiers in history. Discover how Lindsey found her “why” during the most challenging times, pushed her limits, and never stopped learning. Whether you're a sports enthusiast or simply seeking inspiration, Lindsey's story inspires us all to embrace determination, overcome adversity, and chase our dreams.CONNECT with The Resilient Life Podcast:Instagram SUBSCRIBE Get the latest video podcast on YouTubeGet the latest audio podcastCONNECT Ryan Manion on Social Media:Facebook - Twitter - Instagram - LinkedIn  LEARN about Travis Manion FoundationMEET Linsey VonnInstagramLindsey Vonn Foundation

Dale Clark and Ursula Quoyeser join us today to discuss the third annual Fin Feather Fur Food Festival benefiting the Team Gleason Foundation for people living with Amyotrophic Lateral Sclerosis ("ALS"). Team Gleason Foundation was founded by Steve Gleason, a former New Orleans Saints safety who was diagnosed with ALS in 2011. Since its inception that same year, Team Gleason has provided over $40 million to people living with ALS, supplying critically needed mobility equipment such as shower chairs, wheelchair accessories, and power seat elevators, as well as speech generating devices for those who have lost the ability to speak. Dale Clark is a Lafayette native who works as an engineer for Badger Oil. He was diagnosed with ALS in October of 2020. Ursula Quoyeser is also a Lafayette native and was an educator and coach at ESA and other schools before being diagnosed with ALS in July of 2023. The Festival, known as F5, is a cooking competition where teams compete in the Fin, Feather, Fur or Dessert divisions, along with an auction featuring itmes such as season tickets to UL-Lafayette's four major sports, framed jerseys of Drew Brees and Jake Delhomme, a pellet grill with wifi, and much more. Tickets are $45 each and entitle you to taste all 45 teams' food entries along with beer and wine included. F5 was started by Dale and his good friend, Joe Bernard, as a way to help people living with ALS. "Team Gleason was the obvious choice," says Dale, and Joe had experience hosting other F5 events for oil and gas industry charitable fundraisers. Last year F5 raised $170,000 and in the previous inaugural year, $168,000. This year, F5 will be held at Blackham Coliseum on Thursday, April 25, from 4 to 8 pm. That day also features Festival International and Dale encourages people to drop by Blackham Coliseum first before heading out to a night of musical entertainment. You can purchase tickets to F5 by visiting https://www.facebook.com/events/787195629932250 About 5,000 people in the U. S. are diagnosed with ALS each year. It is difficult to diagnose and is often diagnosed by ruling out other diseases, which can take months or years. There is no cure for ALS, which is a fatal neurodegenerative disease in which a person's brain loses connection with the muscles. Symptoms start with a progressive loss of muscle control. ALS kills motor neurons, causing muscles to weaken and eventually paralyze. People with ALS lose their ability to walk, talk, eat and in time, breathe. The average life expectancy is 2 to 5 years once diagnosed. 10% of cases are inherited through a mutated gene; the remaining 90% of cases occur without a family history of ALS. Military veterans are more likely to get ALS. For more information, visit https://www.als.org/ Baseball great Lou Gehrig is one of the iconic heroes who was famously diagnosed with ALS in 1938. He went on to play baseball for a full year before retiring on July 4, 1939, giving his "Luckiest Man" speech. Each year, Lou Gehrig Day is celebrated on June 2 by Major League Baseball, marking the day he became the starting first baseman for the New York Yankees. Here at home, Dale and Ursula are bravely facing ALS and doing all they can to help others with the disease, as well as working to keep up their strength. Dale is relatively lucky, having only lost the use of his right arm and developing hoaresness. Ursula exercises daily by going to Red's Health Club and riding her incumbent bike alongside her Aussie Doodle, who wears goggles in sun to protect its eyes. They both have incredible attitudes and want to do all they can to raise awareness of ALS among us here in Acadiana. They are also both patients of Dr. Stanley H. Appel, a world-renowned neurologist at Houston Methodist, who has been at the forefront of ALS research for decades. In his 90's, Dr. Appel is still working to find a cure for ALS. To all of my awesome family and all my amazing friends,

3/31/2024The Healthy Matters PodcastS03_E10 - Getting a Better Understanding of ALSALS (amyotrophic lateral sclerosis) is a rare but serious condition that affects around 5 people in every 100,000, but due to its devastating effects on both the patient and the caregivers, it's something that certainly merits a deeper conversation.  Lou Gehrig and Steven Hawking may be the two most well-known cases, but it seems once ALS is mentioned, many people are in one way or another connected to it.  But what's actually happening in the body?  What do we think causes it?  What is the progression of the illness like and what are the current treatments available?  There's still a lot out there that we don't know about the disease, but the medical community is making strides every day to help support those living with the condition to lead fulfilling lives. On Episode 10 of the podcast, we'll have an in-depth conversation with Dr. Sam Maiser, MD, Chair of Neurology at Hennepin Healthcare and an expert on ALS, to help us get a better understanding of the disease.  We'll explore what is known and still unknown, what the experience is like for the patient and caregivers, available treatments and resources, and what the future may hold for those living with this disease.  It's a thoughtful conversation with a dedicated specialist on one of medicine's most challenging topics.  We hope you'll join us.You can learn more about ALS and find helpful resources for patients and caregivers here.Got a question for the doc or a comment on the show?Email - healthymatters@hcmed.orgCall - 612-873-TALK (8255)Find out more at www.healthymatters.org

In this podcast, we're going to talk about ALS and how it can negatively affect the body. ALS, also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder that affects nerve cells. This leads to muscle weakness, paralysis, and eventually death. According to "The ALS Puzzle Solved?!", there is evidence that ALS may be related to hormonal shifts and aging. As we age, there is a decrease in protective hormones such as progesterone and melatonin, which can lead to nerve damage and muscle weakness. It has also been suggested that mutations in certain individuals may play a role in the development of ALS. While the exact cause of ALS is still unknown, this information provides a potential pathway for treatment and management of the disease. It is recommended to supplement with melatonin and vitamin K2, as well as take natural B vitamins and hormones such as pregnenolone to support the body's production of progesterone. Additionally, infrared therapy has been shown to potentially increase melatonin levels, while resveratrol can help decrease toxicity in the body. DATA: https://pubmed.ncbi.nlm.nih.gov/30173656 https://pubmed.ncbi.nlm.nih.gov/34138412 https://www.scielo.br/j/ramb/a/hXLP66...

In this episode of Causes or Cures, Dr. Eeks chats with Daniel Barvin, Vice President of Operations and Patient Advocacy at Coya Therapeutics, a trailblazing company working on groundbreaking treatments for ALS and Alzheimer's. In the podcast, Daniel will tell us more about the debilitating and fatal disease ALS and the therapies they are testing at Coya Therapeutics which target T cells, cells that form an important part of the immune system. Daniel's fight against ALS is personal. He has lost several family members to ALS, including his father, uncle, grandfather, and aunt. He is also a carrier of the ALS gene, and realizes it may only be a matter of time until he shows signs of the disease. As a young man now, he discusses what that feels like in the podcast. Daniel also talks about finding a way to have kids with his wife to avoid passing on the ALS gene and finding the group End the Legacy, a not-for-profit organization that provides support and resources for the 1 million individuals with or at risk of genetic ALS and FTD.  Thank you to everyone who reviews and rates the podcast! You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or Twitter.On Youtube.Or Threads.SUBSCRIBE to her newsletter here.Support the show

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Cathleen Lutz, PhD, vice president of the Rare Disease Translational Center at the Jackson Laboratory, provided comment on a recently published study which unveiled that stathmin-2 loss leads to neurofilament-dependent axonal collapse in patients with amyotrophic lateral sclerosis (ALS). Lutz offered insight on the role stathmin-2 may have in this disease, the questions that still remain, and whether restoration of stathmin-2 may be an attractive therapeutic approach. Furthermore, she spoke on the potential of this protein as a disease-modifying biomarker and whether it may be incorporated in trials in the near future.  Looking for more neuromuscular discussion? Check out the NeurologyLive® neuromuscular clinical focus page. Episode Breakdown: 1:15 – Idea behind studying stathmin-2 2:45 – Overviewing study results 7:05 – Next steps in extending this research 8:40 – Neurology News Minute 11:30 – Stathmin-2's connection with neurofilament light 12:55 – Potential of stathmin-2 as ALS-specific biomarker 14:45 – Future use of stathmin-2 in clinical trials 15:30 – Closing thoughts This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Clears Phase 2 KYSA-7 Study of CAR T-Cell Therapy in Refractory Progressive Multiple Sclerosis Dyne Reports Positive Phase 1/2 Data for Duchenne Agent DYNE-251 Parkinson Gene Therapy AB-1005 Meets Primary End Point in Phase 1b Trial VISIONARY-MS Trial Reports CNM-Au8 Improves Vision and Cognition in Multiple Sclerosis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Over the past 12 months, we have shared some remarkable stories from the scientific community, but three of the most impactful have come from “Disruptors” in their respective fields. Relive these stories with our hosts on the year-end edition of Vital Science. Show Notes   The Disruptors: Conversations in Science  Meet Valerie  Meet Wise  Charles River | Gene Therapy for Neurological Disorders  In Vitro and In Vivo Model of Amyotrophic Lateral Sclerosis   https://www.criver.com/eureka/neuroinflammation-in-spinal-cord-injury-a-necessary-evil  W.M. Keck Center for Collaborative Neuroscience    

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Episode 152: ALS FundamentalsFuture Dr. Rodriguez explains the symptoms of ALS, including UMN and LMN symptoms. Dr. Arreaza discusses the principles of symptomatic treatment by primary care. This is a brief introduction to ALS.  Written by Adraina Rodriguez, MSIV, Ross University School of Medicine.  You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Arreaza: It is rare but you may encounter it and you should be able to identify the most common symptoms. ALS Challenge in 2014: Ice bucket challenge. Adriana: Patrick Quinn was an ALS patient and activist who created the ICE Bicket Challenge and helped raise US$220 million for medical research.Arreaza: What is ALS?Adriana: ALS stands for Amyotrophic Lateral Sclerosis, formerly known as Lou Gehrig's Disease. It is the most common form of acquired motor neuron disease. ALS is a progressive, incurable neurodegenerative motor neuron disorder with Upper motor neuron (UMN) and/or Lower motor neuron symptoms that cause muscle weakness, disability, and eventually death. There is no single diagnostic test that can confirm or entirely exclude the diagnosis of motor neuron disease. Arreaza: When should you suspect ALS in a patient?Adriana: The classic patient presentation is insidious, slowly progressive, and unremitting UMN and/or LMN symptoms present in one of four body segments - cranial/bulbar, cervical, thoracic, and lumbosacral - followed by spread to other segments over a period of months to years. Arreaza: What would you see on the physical exam when the Patient is in the clinic? There is a system to send signals from your brain to your muscles. It involves basically two neurons: Upper and lower motor neurons. The UMN goes from your cerebral cortex to your spinal cord and there it connects to a lower motor neuron through synapsis. The LMN then sends the signal to your muscles, causing contraction or relaxation. Tell us about the UMN and LMN symptoms.Adriana:LMN Symptoms: Weakness, Fasciculations, Muscular atrophy, Decreased muscle tone (flaccidity) and reduced or absent reflexes. UMN Symptoms: Increased tone and increased extremity deep-tendon reflexes, presence of any reflexes in muscles that are profoundly weak and wasted, pathological reflexes (crossed adductors, jaw jerk, Hoffman sign, Babinski sign 50%), syndrome of pseudobulbar affect (inappropriate laughing, crying, forced yawning).Arreaza: What are important factors to help narrow your differential to ALS?Multifocal motor neuropathy, cervical radiculomyelopathy, benign fasciculations, inflammatory myopathies, post-polio syndrome, monomelic amyotrophy, hereditary spastic paraplegia, spinobulbar muscular atrophy, myasthenia gravis, hyperthyroidism, and many others.There are pertinent negatives to look out for: Usually negative neuropathic or radiculopathic pain, sensory loss, sphincter dysfunction, ptosis, or extraocular muscle dysfunction (20-30% positive sensory symptoms or “pins and needles” and “electricity” in the affected limbs).Note: Cognitive dysfunction does not exclude ALSArreaza: What are the diagnostic criteria for ALSAdriana: Gold Coast Criteria 2019 proposed over El Escorial criteria:Progressive upper and lower motor neuron symptoms and signs in one limb or body segment, ORProgressive lower motor neuron symptoms and signs in at least two body segments, ANDAbsence of electrophysiologic, neuroimaging, and pathologic evidence of other disease processes that might explain the signs of lower and/or upper motor neuron degeneration.Arreaza: What diagnostic tests should be ordered for further evaluation?Adriana: Electrodiagnostic studies: Electromyogram and nerve conduction studies (EMG and NCS)Laboratory testing: creatine phosphokinase up to 1000u/LNeuroimaging: to exclude other causes mainly. Brain MRI whenever bulbar disease is present. Cervical and lumbosacral spine MRI for LMN findings in the arms and legs.Genetic testing: FALS 10% of ALS defect in C9ORF72 gene that makes motor neuron and brain nerve cell protein, the exact cause is unknown. Arreaza: Finally, how do you treat ALS?Adriana: Disease-modifying treatment: Riluzole is recommended for all patients with ALS. Shown to prolong survival and slow functional deterioration. The mechanisms of action that reduce glutamate-induced excitotoxicity: 1) inhibit glutamic acid release, 2) non-competitive block of N-methyl-D-aspartate (NMDA) receptor-mediated responses, 3) direct action on the voltage-dependent sodium channel. Arreaza: Riluzole is given 50 mg by mouth twice a day. It may cause drowsiness or somnolence, hepatic injury: Not recommended for patients with elevation of transaminases >5 times the upper limit of normal. It is recommended to monitor for hepatic injury and discontinue if there is evidence of liver dysfunction, such as hyperbilirubinemia.Adriana: Symptom-based management is the mainstay of treatment. You may involve a multidisciplinary team to treat the symptoms. For example: palliative, hospice, respiratory function management (Noninvasive Positive Pressure Ventilation vs mechanical ventilation.Arreaza: PCPs may be in charge of managing symptoms because you are the closest provider to the patient. Wherever available, it is recommended to refer your ALS patients to a specialized center. Many patients do not have availability to an ALS center or a neurologist, but they have you to manage their symptoms or complications.Adriana: Dysphagia: It is a common and distressing symptom. It is suggested PEG tube placement for patients with ALS with normal or moderate respiratory function who have dysphagia. It is controversial, some studies found no benefit on survival or quality of life and other studies suggest that it is safe to give a high-carb, hypercaloric diet to ALS patients. Arreaza: Spasticity: Use medications such as baclofen and tizanidine may be helpful, and botulinum injections are an option for those who are not responding to oral muscle relaxants. Adriana: Sialorrhea: Use medications such as atropine, hyoscyamine, amitriptyline, and scopolamine. If these medications are not effective or tolerated, used botox injections into the salivary glands. It is considered safe and useful for treating sialorrhea in patients with ALS. Botox is not only for wrinkles!Arreaza: There are many other symptoms that will require management, but you are invited to review your preferred source of information such as Up to Date, AAFP, or the ALS Association website. ______________________________Conclusion: Now we conclude episode number 152, “ALS Fundamentals.” You heard from future Dr. Rodriguez that ALS can present with upper motor neuron symptoms, such as spastic muscles and hyperreflexia; or lower motor neuron symptoms, such as flaccid and weak muscles. Some other symptoms include dysphagia, shortness of breath, difficulty talking, fatigue, thick mucus, and pseudobulbar affect. Dr. Arreaza explained that primary care physicians are in a special situation to help diagnose and treat the symptoms of ALS, especially in communities with limited access to an ALS center. You may need to involve a multidisciplinary team to improve the quality of life and possibly the survival of ALS patients. This week we thank Hector Arreaza and Adriana Rodiguez. Audio editing by Adrianne Silva.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Galvez-Jimenez, Nestor and Colin Quinn, Symptom-based management of amyotrophic lateral sclerosis, Up To Date, updated on July 31, 2023. https://www.uptodate.com/contents/symptom-based-management-of-amyotrophic-lateral-sclerosis. Royalty-free music used for this episode: Good Vibes: Sky's The limit, downloaded on July 20, 2023 from https://www.videvo.net/ 

Finding more accurate ways to measure ALS progression is one of the most important challenges facing scientists today. More sensitive, objective ways of measuring how the disease is affecting people could help make clinical trials faster and more efficient. Achieving this is one of the primary goals of the ALS Research Collaborative (ARC) – a program at ALS TDI that seeks to learn more about ALS by gathering data about the disease and sharing it with researchers all over the word. One way we do this is to collect movement data by sending people with ALS wearable accelerometers – devices that track movement much like a smart watch. By wearing these devices on each wrist and ankle, participants can generate data about how their disease is affecting their movement over time. Recently, researchers from Massachusetts General Hospital partnered with ALS TDI scientists to analyze these data and demonstrate that these devices can be used as a reliable measure of ALS progression. A paper detailing their findings titled, At-Home Wearables and Machine Learning Sensitively Capture Disease Progression in Amyotrophic Lateral Sclerosis, was published in the journal Nature. To tell us more about this research project and what it means for people with ALS, we're joined by Dr. Anoopum Gupta, a Neurologist at MGH and the paper's lead author.Support the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.

Listen as Dr. London Smith (.com) and his producer Cameron discuss Amyotrophic Lateral Sclerosis with special guest Hyundai Hunter (Ezra Parter).  Sponsored by Caldera + Lab (use code "jockdoc" to get 20% off!). Not so boring! https://calderalab.com/pages/podcast-special-offer?show=Jock+Doc&utm_medium=podcast&utm_source=JocDoc https://www.patreon.com/join/jockdocpodcast Hosts: London Smith, Cameron Clark. Guest: Ezra Parter. Produced by: Dylan Walker Created by: London Smith

On this episode, Karen speaks with Brooke Eby; in March 2023, at the age of 33, Brooke was diagnosed with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, a progressive neurodegenerative disease with no cure. Most doctors give a newly diagnosed person 2-5 years to live. With lots of support from family, friends, and co-workers, Brooke turned her fear and grief into laughter by educating followers on her TikTok account that currently has over 75 thousand followers. Brooke explains through her video reels what she is going through without making it heavy; at the same time, she is creating ALS awareness.

Sarah Langs is currently a research/reporter for MLB.COM. She has also been featured on MLB Network and countless other game broadcasts. She began her career in 2015 as a researcher for ESPN. An avid baseball fan, she is known for demonstrating that “Baseball is the Best.” Her belief is that the people that make up the sport, from players to coaches to scouts to media members make the sport the best there is. She hosts a weekly podcast with her friend and MLB colleague Mandy Bell and continues to promote the game through her powerful social media. In 2021, she was diagnosed with Amyotrophic Lateral Sclerosis, a terminal illness that affects the brain's ability to control her muscles, which atrophy. The people around the sport have rallied around her, and on the anniversary of Lou Gehrig's famous “Luckiest Man on the Face of the Earth” speech, Sarah and her family were honored at Yankee Stadium. Sarah is selling “Baseball is the Best” T-Shirts and other memorabilia at this link bit.ly/FistBumps4ALS. She encourages people to post pictures from baseball games with the shirt or without using the hashtag #FistBumps4ALS. Follow Sarah Langs on social media @SlangsOnSports.

The push for assisted suicide in Canada in the name of compassion has made significant gains in recent years, but the witness of pro-life Catholic Kirsten MacDonald, who was diagnosed with debilitating Amyotrophic Lateral Sclerosis (or ALS, also known as Lou Gherigs disease), demonstrates that every life is worth living, Despite coping with the lack of motor skills caused by ALS, Kirsten McDonald lives a life of vibrant faith and joy, offering her personal sufferings to Christ as a means of sanctification for herself and the world. Join John-Henry Westen in this special episode of the John-Henry Westen Show as he visits Kirsten and her husband David MacDonald in their Canadian home and shows why assisted suicide is no answer at all when it comes to dealing with suffering and hardship.To help Kirsten and her husband David MacDonald manage their health care costs in a nation that promotes assisted suicide, visit: https://www.lifefunder.com/kirstenLOVE LIFESITE? LOVE BEING PRO-LIFE? GET THE FIRST AND ONLY LIMITED EDITION PRO-LIFE SILVER ROUND FROM LIFESITENEWS: https://www.stjosephpartners.com/lifesite-silver-roundSHOP ALL YOUR FUN AND FAVORITE LIFESITE MERCH! https://shop.lifesitenews.com/ HELP US FIGHT THE CENSORSHIP OF BIG TECH: https://give.lifesitenews.com/Connect with us on social media:LifeSite: https://linktr.ee/lifesitenewsJohn-Henry Westen: https://linktr.ee/jhwesten Hosted on Acast. See acast.com/privacy for more information.

What would you do if you knew your days were numbered? In 2019 Dave Warnock, one-time charismatic evangelical preacher now-atheist, was diagnosed with Amyotrophic Lateral Sclerosis. ALS is a fatal condition, and with his diagnosis Dave had a choice to make: live out the rest of his life quietly waiting to die, or “live out loud.” That meant speaking publicly about his spiritual deconstruction, his disease, and dying without a belief in a god or an afterlife.Trigger warning: this conversation speaks frankly about death. We are grateful for the opportunity to share Dave's story with you, and for the time he gave us for this interview that we promise will move and challenge you. Thanks for listening! Now follow us on Twitter, Instagram, Facebook and Threads. And become a Patreon supporter at www.podcastunreasonable.com. It's a small price to pay to keep America from becoming a theocracy, dontchya think?

From a test that lasts an average of 40-minutes, patients with nerve injuries or neuro-muscular conditions can learn a lot about the health of the nerves signaling messages to muscles. The test is called an electromyography, or EMG.  Neurologist Dr. Derrick Fox of MedStar Health explains why the test is useful, who should be tested, what information is gleaned from it, how it is conducted, and more....For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Amyotrophic lateral sclerosis, MultipleSclerosis and Lyme Disease are they one and the same? Is ALS and MS sometimes caused by caused by the Herpes Zoster Virus? In this episode will discuss the possibilities that these life taking diseases may all be related and treatable in a safe though unconventional way.

Amyotrophic lateral sclerosis, MultipleSclerosis and Lyme Disease are they one and the same? Is ALS and MS sometimes caused by caused by the Herpes Zoster Virus? In this episode will discuss the possibilities that these life taking diseases may all be related and treatable in a safe though unconventional way.

Amyotrophic lateral sclerosis, MultipleSclerosis and Lyme Disease are they one and the same? Is ALS and MS sometimes caused by caused by the Herpes Zoster Virus? In this episode will discuss the possibilities that these life taking diseases may all be related and treatable in a safe though unconventional way.

May is ALS Awareness month.  So in the spirit of increasing awareness of ALS, a terminal illness with no cure, I continue my chat with 3 others living with ALS.  We answer the questions sent in by listeners of this podcast about what it's like being a young adult and living with a terminal illness.  My guests, Ashley Rivera and Mira Hudson were diagnosed at 24 and James Smith was diagnosed at 36.  They dig deep and open their hearts to answer your questions like, "Can you share about the moment you were diagnosed with ALS?"  "How do you find the strength day in and out to persevere and overcome fears, pain, negative emotions, etc.? "  "What's important now that wasn't before your diagnosis?"  "What makes you feel inspired or like your best self now?"  and "How are you dealing with the mental side of living with ALS."  Those are a few examples of questions they answer and generate a full conversation around.  Please consider sharing this episode to share their courageous spirits and to tell others about ALS.  Thank you. Hugs, Lorri  

Today on Louisiana Considered, we hear about an upcoming cook-off event in Lafayette to benefit Team Gleason, an organization dedicated to improving life and providing technologies for ALS patients. Plus, we hear about an upcoming art exhibit that celebrates the life of a Baton Rouge native.   This Thursday, the Blackham Coliseum in Lafayette will host the second annual Fin Feather Fur Food Festival – or F5 – a cooking competition. The cook-off also serves to benefit Team Gleason, an organization committed to finding solutions for people living with Amyotrophic Lateral Sclerosis, or ALS. The organization was founded by Steve Gleason, former New Orleans Saints safety who was diagnosed with ALS in 2011.   But while Steve Gleason might be the name you recognize, the F5 cook-off actually all began with two good friends, Joe Bernard and Dale Clark. Upon Dale's diagnosis with ALS, they teamed up to host their first event last year, and now they're making this dream a reality for the second year in a row. They joined Team Gleason's director of development, Kearney Gay, to speak with Louisiana Considered's Alana Schreiber for more.    Derek Gordon, a Baton Rouge native, led an impressive arts career before returning to his hometown to serve with the Arts Council of Greater Baton Rouge. After his passing in 2012, his family approached the Arts Council about what to do with his substantial art collection.    Now, the Arts Council is displaying a selection of 50 works from that 500-work “Derek Gordon and Rodolfo Ramirez Collection.” The exhibition will begin tomorrow, April 27, with an opening reception on May 11th.   Lundyn Herring, curator of the exhibition, and Francine Ramirez, family of Derek Gordon and his late partner Rodolfo Ramirez-Rodriquez, join us to discuss the significance of this collection to the Baton Rouge arts community.    Today's episode of Louisiana Considered was hosted by Adam Vos. Our managing producer is Alana Schreiber and our digital editor is Katelyn Umholtz. Our engineers are Garrett Pittman and Aubry Procell.    You can listen to Louisiana Considered Monday through Friday at 12:00 and 7:30 pm. It's available on Spotify, Google Play, and wherever you get your podcasts.    Louisiana Considered wants to hear from you! Please fill out our pitch line to let us know what kinds of story ideas you have for our show. And while you're at it, fill out our listener survey! We want to keep bringing you the kinds of conversations you'd like to listen to.   Louisiana Considered is made possible with support from our listeners. Thank you!See omnystudio.com/listener for privacy information.

In this episode, we review the high-yield topic of Amyotrophic Lateral Sclerosis ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Neurology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message

I invited Dr. Tom Maniatis, CEO of New York Genome Center and professor at Columbia University, on the podcast. He is also a cofounder of multiple biotech companies. In this episode, we talked about a lot of interesting topics, like recombinant DNA research controversies, ALS (Amyotrophic Lateral Sclerosis) and one of its most famous patient (Dr. Stephen Hawking), biotech business advice, genomic DNA library, Dr. James Watson (one of the discover of the DNA double helix structure), and more. ---------------------------------- Thanks to the partners: Newsly: https://newsly.mepromo code: EARLYMORNING. Anchor https://anchor.fm Libysn https://libsyn.compromo code: DG Dubby Energy https://www.dubby.ggpromo code for 10% off: DIAMONDGOAT spikeview https://www.spikeview.comhttps://www.instagram.com/spikeview ---------------------------------------------------------------------------------- Listen on: Podcast website: https://anchor.fm/diamondgoat Spotify: https://open.spotify.com/show/0EuhA6WyuerHtVAqcFrFeO Google Podcast: https://www.google.com/podcasts?feed=aHR0cHM6Ly9hbmNob3IuZm0vcy80NzE4MzM5MC9wb2RjYXN0L3Jzcw== RadioPublic: https://radiopublic.com/dg-earlymorning-show-WoML4r Breaker: https://www.breaker.audio/dg-early-morning-show Podcast YT channel clips: https://www.youtube.com/@dgearlymorningshow Reason: https://reason.fm/podcast/dg-earlymorning-show Apple Podcast: https://podcasts.apple.com/us/podcast/dg-early-morning-show/id1575451533 Amazon Music: https://music.amazon.com/podcasts/f050b86c-1dad-4bc3-b12f-6aa5fa62438c Tiktok: @dgearlymorningshow -------------------------------------- Check out my other stuff: Instagram: @itzdiamondgoat Twitter: @lildiamondgoat Main YT channel: youtube.com/diamondgoat Tiktok: @lildiamondgoat Soundcloud: @Lil Diamondgoat Spotify: @Lil Diamondgoat Merch store: https://diamondgoat.creator-spring.com --- Support this podcast: https://podcasters.spotify.com/pod/show/diamondgoat/support

This episode features Margarida's interview with Ilary who studies the inhibitory/excitatory changes of the neuronal circuits involved in the pathophysiology of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.

Guy Kawasaki is on a mission to make you remarkable. His Remarkable People podcast features interviews with remarkable people such as Jane Goodall, Neil deGrasse Tyson, Marc Benioff, Woz, Kristi Yamaguchi, and Bob Cialdini. Every episode will make you more remarkable.With his decades of experience in Silicon Valley as a Venture Capitalist and advisor to the top entrepreneurs in the world, Guy's questions come from a place of curiosity and passion for technology, start-ups, entrepreneurship, and marketing. If you love society and culture, documentaries, and business podcasts, take a second to follow Remarkable People.Listeners of the Remarkable People podcast will learn from some of the most successful people in the world with practical tips and inspiring stories that will help you be more remarkable.Listen to Remarkable People here: https://wavve.link/remarkablepeopleText to get notified of new episodes: https://joinsubtext.com/guyLike this show? Please leave us a review -- even one sentence helps! Consider including your Twitter handle so we can thank you personally!Thank you for your support; it helps the show!

On this episode, we review the management of amyotrophic lateral sclerosis (ALS). We discuss riluzole, edaravone, and sodium phenylbutyrate-taurursodiol (Relyvrio) that gained FDA approval in September 2022.  Thanks for listening! We want to give a big thanks to our main sponsor Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. You can find our account at the website below:  www.patreon.com/corconsultrx If you have any questions for Cole or me, reach out to us on any of the following: Text - 415-943-6116 Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com Instagram and other social media platforms - @corconsultrx This podcast reviews current evidence-based medicine and pharmacy treatment options. This podcast is intended to be used for educational purposes only and is intended for healthcare professionals and students. This podcast is not for patients and not intended as advice or treatment.

Imagine you have one child, a beautiful daughter whose life reflects her deep love for Jesus. You and your wife work for a Christian organization, offering the help and hope of the Gospel, seeing every day as an opportunity to encourage and love others. And then you get that phone call that is every parent's nightmare. Your only child, 17 years old, has been in a fatal car accident. Fast forward twenty years and your wife gets a diagnosis that not only will take her life but turn her last years into a place of great anguish. How would you respond? Ellis Goldstein had to answer these questions, the most recent, when he learned his wife's diagnosis of Amyotrophic Lateral Sclerosis, better known as Lou Gehrig's disease. This thoughtful conversation between two men who share the grief of losing a child will challenge listeners with their responses to grief and Ellis' response to the illness and death of his beloved Colleen.

Human endogenous retroviruses (HERVs) are genome-resident relics of ancient infections. They comprise 8% of the human genome, and are activated by viral infections. Proteins like HERV-W and HERV-K accumulate following infections and have been causally connected to Multiple Sclerosis and Amyotrophic Lateral Sclerosis. Scientists have now observed that SARS-CoV2 infection also induces expression of specific HERV proteins. Prof. Claudia Matteucci discusses the role of HERVs and their tie to COVID19 diagnosis and potentially as central players in long COVID. 

Amyotrophic lateral sclerosis, MultipleSclerosis and Lyme Disease are they one and the same? Is ALS and MS sometimes caused by caused by the Herpes Zoster Virus? In this episode will discuss the possibilities that these life taking diseases may all be related and treatable in a safe though unconventional way.

Amyotrophic lateral sclerosis, MultipleSclerosis and Lyme Disease are they one and the same? Is ALS and MS sometimes caused by caused by the Herpes Zoster Virus? In this episode will discuss the possibilities that these life taking diseases may all be related and treatable in a safe though unconventional way.

For Valerie Estess, finding a cure for ALS is personal.Her sister, Jenifer, was diagnosed with this crippling disease in 1998, which led to the founding of Project ALS, a nonprofit designed to raise awareness and eventually find a cure. Nearly 25 years later, they have raised over $100 million and helped develop Jacifusen, the first therapy designed to help treat ALS. However, Valerie believes their work is far from finished.Join us for an intimate discussion on the origins of Project ALS, their collaborative efforts with leading scientists, academic institutions, and contract research organizations to further their knowledge of the disease, and what lies ahead for Project ALS' mission and research.SHOW NOTES Project ALS The Hermstad Legacy: Advances in Treatments for ALS Jaci's Genes Neuroscience Studies S3, E04: From Humble Beginnings to Potential Treatment for ALS Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis

Do you know anyone who has been given an ALS or Lou Gehrig's disease diagnosis? Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ALS is a devastating neurological disorder. World-renowned integrative physician, Lee Cowden, MD, is back to share great news about the latest in […] The post The Latest Holistic ALS Treatment & 2022 Conference, Lee Cowden, MD, McFinn Lovere appeared first on LillianMcDermott.com.